-+ 0.00%
-+ 0.00%
-+ 0.00%

PERSPECTIVE’S [212PB]BAMZIREOTIDE NAVOXETAN (VMT-Α-NET) DEMONSTRATES ENCOURAGING SAFETY, DURABLE DISEASE CONTROL, AND ROBUST TUMOR RESPONSE ACROSS MULTIPLE DOSE COHORTS IN PHASE 1/2A TRIAL IN ADVANCED SSTR2-EXPRESSING NETS

Reuters·10/23/2026 14:51:03